The Globe and Mail reports in its Wednesday, April 1, edition that Novo Nordisk has cut prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 36 per cent and 48 per cent in India to compete with cheaper generics from local manufacturers. A Reuters dispatch to The Globe reports that India's market for diabetes and weight-loss drugs is set for a shake-up after Novo's patent on semaglutide expired on March 20. At least half a dozen Indian drugmakers launched multiple brands of the blockbuster drugs, up to 70 per cent cheaper than Novo's drugs. The average price reduction across doses is 23.8 per cent for Ozempic and 27 per cent for Wegovy, it said. The entry of generics will challenge Novo and Eli Lilly, which launched their diabetes and obesity drugs in India last year, as they try to solidify their market position. Lilly's Mounjaro became India's top-selling drug by value within months of its launch. "This price reduction reflects how innovation can become more accessible when market dynamics evolve," said bariatric surgeon Venu Gopal Pareek, adding that patients might choose Novo's drugs over generics given that it is an original molecule, and if the price difference is not beyond 15 per cent.